Literature DB >> 20666813

The invasive growth potential of residual melanoma and melanoma in situ.

James R DeBloom1, John A Zitelli, David G Brodland.   

Abstract

BACKGROUND: Residual melanoma and melanoma in situ (MIS), also referred to as marginally recurrent melanoma, continues to be a concern for all dermatologic surgeons. Little is known about the potential of these tumors to recur with a deeper invasive histology measured according to Breslow depth.
OBJECTIVE: To identify the clinical features and histologic, invasive potential of marginally recurrent melanoma and MIS. By having a more accurate understanding of marginally recurrent melanoma, we can better appreciate the consequence of inadequate excision and recognize the importance of improving initial treatments.
MATERIALS AND METHODS: An analysis was performed of 108 marginally recurrent melanoma and MIS cases based on prospective data collection. For each case, clinical data, including a comparison of Breslow depth from the time of primary treatment and salvage surgery for marginally recurrent tumor, were tabulated.
RESULTS: Of the 84 lesions initially treated as MIS, 19 (22.6%) recurred marginally with a histologically invasive component and a mean Breslow depth of 0.94 mm. Of the 24 patients diagnosed with invasive melanoma, eight (33.3%) had a deeper Breslow depth at the time of clinical recurrence than at the time of primary treatment. The change in Breslow depth for these eight cases was 1.53 to 2.83 mm.
CONCLUSIONS: Our findings demonstrate the invasive growth potential of MIS and invasive melanoma inadequately excised at the time of primary treatment. This finding illustrates the consequences of marginal recurrence and stresses the importance of accurate and complete removal of melanoma at the time of initial diagnosis and treatment.

Entities:  

Mesh:

Year:  2010        PMID: 20666813     DOI: 10.1111/j.1524-4725.2010.01618.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  5 in total

1.  Mohs Micrographic Surgery Using MART-1 Immunostain in the Treatment of Invasive Melanoma and Melanoma In Situ.

Authors:  Sheila M Valentín-Nogueras; David G Brodland; John A Zitelli; Lorena González-Sepúlveda; Cruz M Nazario
Journal:  Dermatol Surg       Date:  2016-06       Impact factor: 3.398

2.  [Treatment of cutaneous malignant melanoma in the head and neck region : An update].

Authors:  B Frerich
Journal:  HNO       Date:  2018-11       Impact factor: 1.284

Review 3.  Diagnosis and management of lentigo maligna: a review.

Authors:  Julia M Kasprzak; Yaohui G Xu
Journal:  Drugs Context       Date:  2015-05-29

4.  An assessment of histological margins and recurrence of melanoma in situ.

Authors:  Kenneth M Joyce; Cormac W Joyce; Deirdre M Jones; Paul Donnellan; Alan J Hussey; Padraic J Regan; Jack L Kelly
Journal:  Plast Reconstr Surg Glob Open       Date:  2015-03-06

Review 5.  Current perspectives on Mohs micrographic surgery for melanoma.

Authors:  Derek Beaulieu; Ramin Fathi; Divya Srivastava; Rajiv I Nijhawan
Journal:  Clin Cosmet Investig Dermatol       Date:  2018-06-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.